Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (41)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Laack, E.
Right arrow Articles by Hossfeld, D. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laack, E.
Right arrow Articles by Hossfeld, D. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1550-1557, 2002
© 2002 European Society for Medical Oncology

Original Paper

Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer

E. Laack1,+, A. Köhler1, C. Kugler2, T. Dierlamm1, C. Knuffmann1, G. Vohwinkel1, A. Niestroy1, N. Dahlmann3, A. Peters4, J. Berger5, W. Fiedler1 and D. K. Hossfeld1

1 Department of Oncology and Haematology, University Hospital Hamburg-Eppendorf; 2 Department of Surgery, 3 Department of Laboratory Medicine and 4 Department of Pathology, General Hospital Hamburg-Harburg; 5 Institute of Mathematics and Computer Science in Medicine, University Hospital Hamburg-Eppendorf, Germany

Received 17 December 2001; revised 5 April 2002; accepted 25 April 2002

Background:

Matrix metalloproteinase (MMP)-9 and vascular endothelial growth factor (VEGF) are two proteins involved in angiogenesis. In the present study we investigated the association of pretreatment MMP-9 and VEGF serum levels with clinicopathological parameters and outcome in patients with non-small-cell lung cancer (NSCLC).

Patients and methods:

From February 1998 to October 1999, pretreatment serum levels of MMP-9 and VEGF were analysed in 118 patients with enzyme-linked immunoassays. At diagnosis 50 patients (42%) were staged as early disease (I/II), 27 patients (23%) as locally advanced (IIIA/IIIB), and 41 patients (35%) had metastatic disease (IV). In 72 of the 118 patients tumours were resected and 46 patients received combination chemotherapy with gemcitabine and vinorelbine.

Results:

The median survival of all 118 patients was 602 days. The 72 patients who had undergone surgery had a median survival of 972 days and the 46 patients who were treated with chemotherapy had a median survival of 298 days (P <0.001). Resected patients with stage I/II disease and an MMP-9 serum level <=1293 ng/ml or a VEGF serum level <=630 pg/ml had a significantly longer survival (median survival longer than 1218 days) than patients with higher serum levels (median survival 421 days) (P = 0.001 for MMP-9; P = 0.04 for VEGF). No significant difference in survival was observed in patients with resected stage III disease. Besides tumour stage, Karnofsky performance status and gender, the pretreatment serum level of MMP-9 was identified as an independent prognostic factor in a multivariate Cox regression analysis.

Conclusions:

Future studies may support our hypothesis that the pretreatment serum level of MMP-9 is a new powerful prognostic marker and can help to stratify NSCLC patients with stage I/II disease into low- and high-risk groups.

Key words: angiogenic factors, matrix metalloproteinase-9, non-small-cell lung cancer, prognostic factors, vascular endothelial growth factor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
J. H. Park, K. J. Park, Y. S. Kim, S. S. Sheen, K. S. Lee, H. N. Lee, Y. J. Oh, and S. C. Hwang
Serum Angiopoietin-2 as a Clinical Marker for Lung Cancer
Chest, July 1, 2007; 132(1): 200 - 206.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Chetty, P. Bhoopathi, P. Joseph, S. Chittivelu, J. S. Rao, and S. Lakka
Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice.
Mol. Cancer Ther., September 1, 2006; 5(9): 2289 - 2299.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Nikkola, P. Vihinen, M.-S. Vuoristo, P. Kellokumpu-Lehtinen, V.-M. Kahari, and S. Pyrhonen
High Serum Levels of Matrix Metalloproteinase-9 and Matrix Metalloproteinase-1 Are Associated with Rapid Progression in Patients with Metastatic Melanoma
Clin. Cancer Res., July 15, 2005; 11(14): 5158 - 5166.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
A. Yoshimoto, K. Kasahara, M. Nishio, T. Hourai, T. Sone, H. Kimura, M. Fujimura, and S. Nakao
Changes in Angiogenic Growth Factor Levels After Gefitinib Treatment in Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., May 1, 2005; 35(5): 233 - 238.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Ruokolainen, P. Paakko, and T. Turpeenniemi-Hujanen
Tissue Inhibitor of Matrix Metalloproteinase-1 Is Prognostic in Head and Neck Squamous Cell Carcinoma: Comparison of the Circulating and Tissue Immunoreactive Protein
Clin. Cancer Res., May 1, 2005; 11(9): 3257 - 3264.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.